Sign In
Buy MGNX
$4.69
+0.110 (+2.40%)
At Close: Jun 23, 2026
Benzinga's Top Ratings Upgrades, Downgrades For July 11, 2022
03:53pm, Monday, 11'th Jul 2022 Benzinga
Upgrades
For Visteon Corp (NASDAQ:VC), Exane BNP Paribas upgraded the previous rating of Neutral to Outperform. For the first quarter, Visteon had an EPS of $1.09, compared to year-ago quarter EPS of
Why MacroGenics Stock Tumbled Today
12:28pm, Monday, 11'th Jul 2022
One of its phase 2 clinical trials was ended abruptly after several patients died.
Patient Death Prompts MacroGenics To Close Mid-Stage Head & Cancer Study
06:42am, Monday, 11'th Jul 2022
MacroGenics Inc (NASDAQ: MGNX) closed the Phase 2 study (CP-MGA271-06) of enoblituzumab in the first-line treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and
MacroGenics Announces Closure of CP-MGA271-06 Study Evaluating Enoblituzumab plus Checkpoint Inhibition in Head and Neck Cancer
08:30pm, Friday, 08'th Jul 2022 GlobeNewswire Inc.
ROCKVILLE, MD, July 08, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the
Why MacroGenics Stock Is Skyrocketing Today
05:10pm, Tuesday, 21'st Jun 2022 The Motley Fool
Investors like that a key insider is buying shares of the biotech.
MacroGenics to Participate in Upcoming Investor Conference
04:01pm, Wednesday, 08'th Jun 2022
ROCKVILLE, MD, June 08, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the
MacroGenics Announces Appointment of William Heiden to Board of Directors
08:01pm, Monday, 23'rd May 2022 GlobeNewswire Inc.
ROCKVILLE, MD, May 23, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the
MacroGenics to Participate in Upcoming Investor Conference
04:01pm, Tuesday, 17'th May 2022
ROCKVILLE, MD, May 17, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the t
Benzinga's Top Ratings Upgrades, Downgrades For May 5, 2022
02:03pm, Thursday, 05'th May 2022 Benzinga
Upgrades
According to Tudor Pickering, the prior rating for ProPetro Holding Corp (NYSE:PUMP) was changed from Hold to Buy. In the first quarter, ProPetro Holding showed an EPS of $0.11, compared to $
6 Analysts Have This to Say About Macrogenics
06:05pm, Wednesday, 04'th May 2022 Benzinga
Macrogenics (NASDAQ:MGNX) has observed the following analyst ratings within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
2
4
0
0
0
Last 30D
Why MacroGenics Stock Is Tanking Today
04:47pm, Wednesday, 04'th May 2022 The Motley Fool
Investors found plenty to dislike about the company's Q1 update.
Benzinga's Top Ratings Upgrades, Downgrades For May 4, 2022
02:17pm, Wednesday, 04'th May 2022 Benzinga
Upgrades
Craig-Hallum upgraded the previous rating for Pros Holdings Inc (NYSE:PRO) from Hold to Buy. Pros Holdings earned $0.21 in the first quarter, compared to $0.22 in the year-ago quarter. At the
MacroGenics, Inc. (MGNX) CEO Scott Koenig on Q1 2022 Results - Earnings Call Transcript
11:22pm, Tuesday, 03'rd May 2022
MacroGenics, Inc. (NASDAQ:MGNX ) Q1 2022 Earnings Conference Call May 3, 2022 4:30 PM ET Company Participants Chris James - Vice President, Investor Relations and Corporate Communications Scott Koenig
MacroGenics (MGNX) Reports Q1 Loss, Lags Revenue Estimates
09:15pm, Tuesday, 03'rd May 2022 Zacks Investment Research
MacroGenics (MGNX) delivered earnings and revenue surprises of -28.57% and 35.46%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
MacroGenics (MGNX) Reports Q1 Loss, Lags Revenue Estimates
06:49pm, Tuesday, 03'rd May 2022
MacroGenics (MGNX) delivered earnings and revenue surprises of -28.57% and 35.46%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
